<DOC>
	<DOCNO>NCT01792687</DOCNO>
	<brief_summary>This Phase Ib , open label study ARN-509 administer combination abiraterone acetate prednisone patient metastatic castration-resistant prostate cancer .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Preliminary Anti-tumor Activity Ascending Doses ARN 509 Combination With Abiraterone Acetate</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Key Participants must histologically confirm prostate cancer . Radiographic evidence metastatic disease , detectable bone scan , CT scan , MRI . At least one site metastatic disease must amenable needle biopsy . Castrate level testosterone ( testosterone &lt; 50 ng/dL ) androgen deprivation therapy ( ADT ) . Patients undergone orchiectomy continue gonadotropin release hormone ( GnRH ) agonist antagonist therapy . Age &gt; 18 year ECOG performance status &lt; 2 Evidence disease progression ADT . Patients must two serial rise PSA nadir , least 1 week PSA measurement , minimum PSA 2 ng/mL , OR patient must radiographic evidence progression . Nadir define low PSA value begin recent therapy metastatic CRPC . Key Participants chemotherapy radiotherapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier . Participants may receive study agent . Participants know brain metastases Any history seizure condition may predispose seizure ( e.g. , prior stroke within 1 year prior randomization , brain arteriovenous malformation , Schwannoma , meningioma , benign CNS meningeal disease may require treatment surgery radiation therapy ) . Concurrent therapy medication know seizure potential ( must discontinue substitute least 28 day prior start trial ) Concurrent treatment strong CYP3A4 inhibitor ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconazole , grapefruit juice ) inducer ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. John 's Wort ) History pituitary dysfunction History adrenal dysfunction Requirement steroid use great 10 mg prednisone daily History gastrointestinal disorder prior extensive gastrointestinal surgery may interfere sufficient absorption study compound . Prior history CYP17 inhibitor ( e.g. , abiraterone acetate , TAK700 ) secondgeneration antiandrogen ( e.g. , MDV3100 )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic castrate resistant prostate cancer ( CRPC )</keyword>
</DOC>